Tag Archive for: Clinical

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform

/in

Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement 17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a […]

Read more

Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition

/in

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably […]

Read more

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

/in

Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial – a trial evaluating LTX-315, Lytix’s lead drug candidate. Read more…..

Read more

STORM Therapeutics announces closing of USD $30M Series B financing

/in

Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias  Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification 14 December 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying […]

Read more